Short answer
Amylyx Pharmaceuticals, Inc. (AMLX) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $0 (down 100.0% year over year) with net income of −$34M.
Q3 2025 key financials · XBRL
- Revenue
- $0
- −100.0% YoY
- Net income
- −$34M
- +52.7% YoY · +17.0% QoQ
- EPS (diluted)
- −$0.37
- +65.4% YoY · +19.6% QoQ
Source: XBRL data from the Amylyx Pharmaceuticals, Inc. (AMLX) Q3 2025 10-Q on SEC EDGAR. USD.
Amylyx Pharmaceuticals, Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New tax law impact from the One Big Beautiful Bill Act (OBBBA) signed July 4, 2025, altering R&D expense capitalization and deductions
- Most material update: cessation of RELYVRIO/ALBRIOZA sales after Phase 3 PHOENIX failure, eliminating prior $380.8M 2023 revenue source
- Regulatory risk heightened by FDA and other authorities’ lengthy approval processes delaying avexitide, AMX0035 commercialization in multiple jurisdictions
- Near-term risk from reliance on third parties for clinical trials and manufacturing, risking delays in product supply and approvals for avexitide and AMX0035
- Financial risk from liquidity: cash runway into 2028 but no committed additional capital, risk of dilution or unfavorable terms when raising future funds
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Amylyx Pharmaceuticals, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.